For years, employers have focused on preventing huge health bills that can result from their older workers. But now Leonard Hoops, the CEO of Visit Indy, is trying to get employers to focus on the costs of the youngest members of their health plans: premature babies.
Through partnerships with county-owned hospitals, Indiana’s nursing homes pulled in about $260 million last year in extra federal funds. That means participating nursing homes enjoyed a 10 percent bonus check.
After cutting staff sharply in 2013, Franciscan enjoyed more revenue and big profits in 2014. The key question for its and other hospitals’ future is whether they can keep up these gains in productivity to handle looming payment cuts from Obamacare.
An Indianapolis exporter that stood to take a hit from the strong dollar is faring well, thanks to a strategy honed in two prior cycles when the currency stood tall.
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
The future of U.S. health care will be about precision and parsimony. And Roche Diagnostics Corp. think its new line of DNA-level testing machines are just what the doctor ordered.
The U.S. Department of Justice told Lilly last month its investigation was over—more than a year after the drugmaker paid $29 million to the SEC to settle related bribery allegations.
Getting upfront price estimates from hospitals has been a nightmare for consumers, but hospitals are starting to give them out more often. Community Health Network is even promoting its price-estimating service on its website.
The Legislative Services Agency predicts a three-year ban on new skilled nursing beds would save the state $2.2 million—not the $24.6 million reported by the state in December.
A sleepy season for Obamacare sign-ups will end on Sunday will overall enrollment almost exactly where insurers predicted it would be. But low-priced plans, such as Ohio-based CareSource, have scooped up far more customers than expected.
St. Vincent’s operations produced a healthy profit margin of 10 percent last year, but nearly half of that money—$134 million—was shipped to Ascension Health, St. Vincent’s parent organization. That’s nearly 5 percent of what Hoosiers and their health plans pay for care at St. Vincent each year.
Leaders of the IU Health hospital system have discussed recently, according to multiple sources, whether a closer partnership with Eskenazi Hospital might be just what the doctor ordered.
An estimated 40,000 Hoosiers who already bought health insurance on the Obamacare exchanges now must end those plans and enroll in the expanded Healthy Indiana Plan. Otherwise, they’ll be on the hook to pay back thousands of dollars in Obamacare tax credits.
Tristan Coram, 34, research scientist for Dow AgroSciences, works to boost global crop production.
Indiana’s health care companies attracted $103.8 million in investments last year, the highest total since attracting 2007. However, all but $3 million of last year’s investments came during the first six months of the year and Indiana continued to lag other Midwest states.
When the U.S. Supreme Court hands down its ruling on Obamacare’s tax credits, it could zap nearly $1 billion from Hoosiers’ finances. In fact, Hoosiers buyers on Obamacare’s exchanges have more to lose, as a percentage of their incomes, than the residents of all states other than Alaska and Mississippi.
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Nearly half of all Hoosier workers covered by employer health plans are now enrolled in high-deductible, consumer-directed health plans, according to a new survey. That means the state is about to pass the point of no return on transforming health care into a real marketplace.
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
The Indianapolis-based drugmaker said its long-term strategy is on track, but predicted sales this year would be $20.3 billion to $20.8 billion, a shade below what Wall Street was expecting.
